ActRight

The rising geriatric population, who are more prone to developing chronic diseases, is primarily driving the rifampicin market. Rifampicin is extensively used to treat joint, bone, and catheter-related infections. Moreover, the increasing prevalence of tuberculosis (TB) among the masses is stimulating the market growth. Besides this, various innovations, such as the development of effective rifampicin with improved safety and efficacy, hence making it a suitable treatment option for children, are positively impacting the global market.